Drug Profile
Research programme: anti-interleukin-18 monoclonal antibodies - CAT
Latest Information Update: 24 Jan 2013
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 18 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 24 Jan 2013 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
- 22 Jun 2006 No development reported - Preclinical for Inflammation in United Kingdom (unspecified route)
- 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca